Susvimo: Withdrawal of the marketing authorisation application



Roche Registration GmbH withdrew its application for a marketing authorisation of Susvimo for the treatment of neovascular (wet) age-related macular degeneration (AMD). 

The company withdrew the application on 2 May 2023.

Key facts

Product number
International non-proprietary name (INN) or common name
  • ranibizumab
Active substance
  • ranibizumab
Date of withdrawal
Company making the application
Roche Registration GmbH
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating